Zafgen, Inc., a Cambridge, Mass.-based pharmaceutical company developing novel obesity therapeutics, has closed a $33m Series C financing.
The round was led by existing investors Atlas Venture and Third Rock Ventures.
The company intends to use the funds to advance its pipeline and develop its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into Phase 2 clinical studies.
Founded in 2005, and led by president and CEO Thomas Hughes, Ph.D., Zafgen is pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism. Its approach focuses on restoring control of key metabolic processes, releasing stored fat which then is used by the body as fuel.